Findings

What do systematic reviews say?

18 questions · 21 findings · 3 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3 · 14.3%GRADE not reported 0 · 0%Very low 5 · 23.8%Low 13 · 61.9%Moderate 0 · 0%High 0 · 0%

Closest answers

The findings closest to your search, judged one by one by TypeSafe's Jev model.

Direct match · question page
- Memantine vs placebo · Depression rating scale score ‐ at 3 months
  Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 157 participants
  Low
Direct match · question page
- Comparison 2: memantine vs placebo · Cognitive abilities (various scales)
  Pharmacological interventions for cognitive decline in people with Down syndrome 2015 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 184 participants
  Low
Direct match · question page
- Memantine vs placebo · Core symptoms of autism
  Memantine for autism spectrum disorder 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 181 participants
  Very low
Direct match · question page
- Memantine vs placebo · Irritability
  Memantine for autism spectrum disorder 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 121 participants
  Low
Direct match · question page
- Comparison 2: memantine vs placebo · Behavioural problems (various scales)
  Pharmacological interventions for cognitive decline in people with Down syndrome 2015 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 186 participants
  Low

Memantine vs placebo

Core symptoms of autism · Children aged 6 to 18 years with ASD

1 finding from 1 review

Memantine for autism spectrum disorder 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 181 participants
Very low

Memantine vs placebo

Adverse effects sufficient to stop treatment · Children aged 6 to 18 years with ASD

Memantine showed no clear difference in adverse effects Assessed by the study authors as those that were… compared with placebo (low certainty).

1 finding from 1 review

Memantine for autism spectrum disorder 2022 · Cochrane Headline outcomes only
OR 0.64 [0.17, 2.39]
2 studies · 144 participants
Low

Memantine vs placebo

Language · Children aged 6 to 18 years with ASD

1 finding from 1 review

Memantine for autism spectrum disorder 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 144 participants
Low

Memantine vs placebo

Memory (specific cognitive function) · Children aged 6 to 18 years with ASD

1 finding from 1 review

Memantine for autism spectrum disorder 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 23 participants
Low

Memantine vs placebo

Adaptive behaviour · Children aged 6 to 18 years with ASD

1 finding from 1 review

Memantine for autism spectrum disorder 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 23 participants
Low

Memantine vs placebo

Hyperactivity · Children aged 6 to 18 years with ASD

1 finding from 1 review

Memantine for autism spectrum disorder 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 121 participants
Low

Memantine vs placebo

Irritability · Children aged 6 to 18 years with ASD

1 finding from 1 review

Memantine for autism spectrum disorder 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 121 participants
Low

Memantine vs placebo

Efficacy: number of participants who respond to treatment ‐ at 3 months · adults (aged 18 years+) with depression in bipolar disorder

It is very uncertain whether memantine changes efficacy: number of participants who respond to treatment ‐ at 1 week compared with placebo (very low certainty).

4 findings from 1 review

Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder 2021 · Cochrane Headline outcomes only
OR 1.08 [0.06, 19.05]
1 study · 29 participants
Very low
Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder 2021 · Cochrane Headline outcomes only
OR 4.88 [0.78, 30.29]
1 study · 29 participants
Very low
Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder 2021 · Cochrane Headline outcomes only
OR 5.33 [1.02, 27.76]
1 study · 29 participants
Very low

Show 1 more finding

Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder 2021 · Cochrane Headline outcomes only
OR 1.66 [0.69, 4.03]
2 studies · 261 participants
Low

Memantine vs placebo

Remission · adults (aged 18 years+) with depression in bipolar disorder

It is very uncertain whether memantine changes efficacy: number of participants who achieve remission ‐ at 1 week compared with placebo (very low certainty).

1 finding from 1 review

Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder 2021 · Cochrane Headline outcomes only
OR 1.08 [0.06, 19.05]
1 study · 29 participants
Very low

Memantine vs placebo

Depressive symptoms · adults (aged 18 years+) with depression in bipolar disorder

1 finding from 1 review

Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 157 participants
Low

Memantine vs placebo

Acceptability ‐ total dropouts · adults (aged 18 years+) with depression in bipolar disorder

Memantine showed no clear difference in acceptability: total dropouts compared with placebo (low certainty).

1 finding from 1 review

Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder 2021 · Cochrane Headline outcomes only
OR 0.77 [0.45, 1.31]
2 studies · 261 participants
Low

Memantine vs placebo

Acceptability ‐ dropouts due to adverse effects · adults (aged 18 years+) with depression in bipolar disorder

Memantine showed no clear difference in acceptability: dropouts due to adverse effects compared with placebo (low certainty).

1 finding from 1 review

Ketamine and other glutamate receptor modulators for depression in adults with bipolar disorder 2021 · Cochrane Headline outcomes only
OR 0.34 [0.01, 8.34]
1 study · 232 participants
Low

Memantine vs placebo

Carer stress · people with Down syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for cognitive decline in people with Down syndrome 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Memantine vs placebo

Institutional/home care · people with Down syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for cognitive decline in people with Down syndrome 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Memantine vs placebo

Death · people with Down syndrome

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for cognitive decline in people with Down syndrome 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Memantine vs placebo

Secondary outcome measure: cognitive abilities at the end of · people with Down syndrome

1 finding from 1 review

Pharmacological interventions for cognitive decline in people with Down syndrome 2015 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 184 participants
Low

Memantine vs placebo

Behavioural problems: overall · people with Down syndrome

1 finding from 1 review

Pharmacological interventions for cognitive decline in people with Down syndrome 2015 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 186 participants
Low

Memantine vs placebo

Adverse events · people with Down syndrome

Comparison 2: memantine showed no clear difference in adverse events compared with placebo (low certainty).

1 finding from 1 review

Pharmacological interventions for cognitive decline in people with Down syndrome 2015 · Cochrane Headline outcomes only
OR 0.45 [0.18, 1.17]
2 studies · 211 participants
Low